Mabwell Bioscience-B
02493 · HKEXInnovative biotech focused on oncology & age-related diseases; core Nectin-4 ADC 9MW2821 in pivotal Phase III; 4 biosimilars launched
IPO Timeline
- OpenApr 20
- CloseApr 22
- AllotmentApr 24
- PaymentApr 28
- ListingApr 28
Key Facts
Issue Price
HKD 30.71
Min Entry Fee
HKD 5,583.74
Shares Issued
47.13M
Lot Size
200
Total Raise
HKD 1447.4M
Estimated Market Cap
—
Public Allocation
10.0%
International Placement
90.0%
Business Overview
Innovative biotech focused on oncology & age-related diseases; core Nectin-4 ADC 9MW2821 in pivotal Phase III; 4 biosimilars launched
Use of Proceeds
1) 56.8% for clinical development of 9MW2821 for multiple indications across phases;
2) 17.7% for R&D of other pipeline assets in oncology & age-related diseases with high clinical need;
3) 15.5% for commercialization;
4) 10.0% for working capital and general corporate purposes
Sponsor Track Record
| Name | Past Deals | First Day Avg % | Break Rate % | 30-Day Avg % |
|---|---|---|---|---|
| 中金香港 | 28 | 12.4 | 21.4 | 8.6 |
| 中信里昂 | 19 | 9.7 | 26.3 | 5.1 |
| 建银国际 | 14 | 6.2 | 35.7 | 1.8 |
Baseline updated: 2026-04-15
Intermediaries & Documents
Sponsors
- CITIC Securities (Hong Kong) Limited, Haitong International Capital Limited
Underwriters
- CITIC Securities (Hong Kong) Limited
- Haitong International Capital Limited
- Industrial Securities International Securities Limited
- CMB International Finance Limited
- CCB International Finance Limited
Prospectus PDF
Prospectus PDF →Cornerstone Investors
- Junshi Hong Kong Limited
- Sanjin International Co., Ltd.
- Guohui (Hong Kong) Holdings Co., Limited
- Changrong International Co., Limited
- WuXi Biologics HealthCare Venture Limited
- Jin Xiu Zhong He (Beijing) Capital Management Co., Ltd.
Total
0
30.2% of placement
BBX does not participate in the allocation process for any IPO listed on this page. This page is for informational purposes only and is not investment advice.